Clinical trials are critical to developing and evaluating new treatments for rare diseases. Scientists, however, often do not have enough information about the symptoms and biology of rare diseases to design clinical trials. NCATS, working with the Eunice Kennedy Shriver National Institute of Child Health and Human Development, created the Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes grants to address some of the obstacles scientists face. These obstacles include, among other issues, gaps in our understanding of a rare disease’s natural history and a lack of suitable biomarkers or clinical outcome measures.
Through these grants, NCATS seeks to facilitate rare disease research by enabling efficient and effective movement of candidate therapies or diagnostics toward clinical trials and to increase their likelihood of success. These grants are modeled after a grant program at the National Institute of Neurological Disorders and Stroke.
Contact: Alice Chen Grady, M.D.
Current Funding Opportunities
- Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes (R03 Clinical Trial Not Allowed) PAR-18-952 · Posted Date: 10/04/2018
- Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes (R21 Clinical Trial Not Allowed) PAR-18-953 · Posted Date: 10/04/2018
Learn about related programs:
- Rare Diseases Clinical Research Network – The RDCRN supports consortia of medical research centers that work together to investigate groups of related rare diseases.
- Therapeutics for Rare and Neglected Diseases – The TRND program supports preclinical development of therapeutic candidates intended to treat rare or neglected disorders.